Table 1—

Clinical and laboratory characteristics of 109 patients with type 2 diabetes attending a single tertiary referral clinic with a GFR <60 ml · min−1 · 1.73 m−2

Normo-albuminuriaMicro-albuminuriaMacro-albuminuriaP
n433828
AER (μg/min)9.3 ×/÷ 1.161 ×/÷ 1.2671 ×/÷ 1.2<0.0001
Age (years)73 ± 172 ± 267 ± 2<0.01
Females (%)564518<0.01
Duration of diabetes (years)14 ± 116 ± 115 ± 20.64
BMI (kg/m2)30.8 ± 1.029.3 ± 0.731.6 ± 1.40.26
Retinopathy (%)2650410.11
CHD (%)4951640.42
CVD (%)2127180.67
PVD (%)2335460.12
Smoking (%)3853620.19
HbA1c (%)7.3 ± 0.37.9 ± 0.27.9 ± 0.30.23
SBP (mmHg)138 ± 3147 ± 3147 ± 30.02*
DBP (mmHg)75 ± 278 ± 177 ± 10.37
TC (mmol/l)4.4 ± 0.24.5 ± 0.24.3 ± 0.20.91
LDL-C (mmol/l)2.6 ± 0.12.8 ± 0.12.5 ± 0.20.43
HDL-C (mmol/l)1.15 ± 0.051.19 ± 0.060.97 ± 0.050.02*
TG (mmol/l)1.9 ×/÷ 1.11.8 ×/÷ 1.12.0 ×/÷ 1.10.86
GFR (ml · min−1 · 1.73 m−2)47 ± 247 ± 239 ± 20.01
Creatinine (μmol/l)110 (87–146)112 (101–136)150 (123–200)0.001
RAS inhibitor (%)7474810.76
Anti-HT (%)9595960.95
  • Data are mean ± SEM, geometric mean ×/÷ tolerance factor, or median (interquartile range). Patients were stratified on the basis of AER, i.e., normo- (<20 μg/min), micro- (20–200 μg/min) and macroalbuminuria (>200 μg/min).

  • *

    * After adjustment for differences in age or sex, there were no significant differences in SBP (P = 0.15) or HDL-C (P = 0.66). CHD, coronary heart disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides.